detection was performed retrospectively after successful IMinduced suppression of the BCR-ABL clone and after a shift of phenotype had occurred during treatment. [2] [3] [4] [5] Occasionally BM biopsies are able to identify a Ph þ -CML/Ph À -CMPD case already at presentation. A 45-year-old male (#4) got a BM biopsy in order to clarify leukocytosis (WBC 57.54 Â 10 9 l À1 ).The BM analysis revealed a CML with BCR-ABL transcript (b3a2) with a massive granulocytosis but also with unusually large and clustering megakaryocytes that are not characteristic for CML but for Ph À -CMPD ( Figure 1 ). Consequently, a JAK2 V617F analysis was initiated although no thrombocytosis was evident (platelet count 266 Â 10 9 l À1 ). A concurrent JAK2 V617F mutation (43% allele frequency) could be demonstrated. The therapy was started with IM and 8 months later the molecular remission of the Ph þ -CML was achieved while JAK2 V617F was still detectable (data not shown).
The frequency of BCR-ABL transcript and concurrent JAK2 V617F might be low in CMPD but probably more frequent than indicated by the first published series of JAK2 V617F mutation in CMPD. In this study we analysed 33 randomly selected Ph þ -CML cases and previously we have also analysed 87 randomly selected cases. 2 3 The co-stimulatory receptor CD137 suppresses T-cell-dependent humoral immune responses in vivo, and ligation of an agonistic antibody to CD137 has proven effective in mouse models of chronic cutaneous GVHD, allergic asthma, collagen-induced arthritis and systemic lupus erythematosus. 4 In addition to their immunosuppressive effect, MSCs possess the ability to differentiate into a variety of tissues and to serve as a source for tissue repair. 5 Whereas MSCs from patients with SSc show immunosuppressive capacities similar to those of healthy individuals, their ability to differentiate into endothelial progenitor cells and to contribute to vasculogenesis has been shown to be impaired.
We are the first to report on the feasibility, safety and, most notably, efficacy of transplanting bone marrow-derived human
MSCs from an allogeneic haploidentical-related donor after in vitro expansion into a patient suffering from an autoimmune disease in general and SSc with diffuse cutaneous involvement. We present data suggesting ligation of CD137L to its receptor CD137 as a possible mechanism responsible for the immunosuppression.
A 41-year-old female patient first experienced Raynaud's syndrome in 2001. SSc was diagnosed in 2002. The disease was refractory to methotrexate, steroids, azathioprine, supportive measures and psoralen UVA (PUVA). Before transplantation in September 2006, she presented with 6 painful ulcerations (covering a surface of 17 cm 2 in total) at acral localizations (fingertips, knuckles, Figure 1) , acral sclerosis (a rapidly progressive massive involvement of the skin, including arms, thighs, the whole trunk and the tendons and joints. The 17 site modified Rodnan skin score was 25. The titre of anti-Scl70-antibodies was elevated. At the time of transplantation, the patient received a daily dose of 7.5 mg prednisolone and 100 mg azathioprine. During and after the intravenous administration of 10 6 MSCs per kilogram bodyweight (6 Â 10 7 MSCs total), the patient was without subjective complaint or objective organ dysfunction as was the case during further observation (1 year as of 13 September 2007). Remarkably, a common cold occurring 6 months after transplantation was resolved without the need for further medical measures. The patient experienced a subjective improvement in her condition. She felt her tendons and muscles less stiff and her hands more frequently warm. Three months after transplantation, a significant decrease in the patient's painful ulcerations was measured. After 6 months, we detected only 1 ulceration covering a surface of 0.4 cm 2 ( Figure 1 ). Vascular ultrasound 6 months after transplantation revealed a marked improvement in the blood circulation of hands and fingers. Notably, the transcutaneous partial oxygen pressure (tcpO 2 ) was enhanced by 20 mm Hg on the left hand and 25 mm Hg on the right hand, now showing physiological values. The resistance index fell, indicating reduced peripheral vascular resistance (Figure 2 ). The Rodnan skin score was reduced from 25 to 11. This was paralleled by a reduction of the visual analogue scale for pain from 5.5 to 2.2, a decrease in the Valentini activity score from 4.5 to 1.5 and an improvement of the health assessment questionnaire from 19 to 26 points. Pulmonary function tests remained normal. The titre of antiScl70-antibodies remained elevated. Low absolute T-lymphocyte, B-lymphocyte and NK cell counts were measured before and after transplantation (data not shown), which did not change during the period of observation. Remarkably, 14 days after transplantation, a sharp increase in both the relative CD4 þ / CD137L þ as well as the relative CD8 þ /CD137L þ count was 
Figure 2
Representation of results of vascular ultrasound before and 6 months after transplantation.
Letters to the Editor measured ( Figures 3 a and b) . In conclusion, the data shown in this report are encouraging and support the claim for phase I/II trials of allogeneic MSCs against severe SSc and autoimmune diseases in general. The mechanism behind this phenomenon has to be investigated through larger studies. We hypothesize that both selective immunosuppression through MSCs, perhaps through an increase in CD137L þ T-lymphocytes, as well as regeneration of impaired endothelial progenitors, contribute to the striking improvement our patient experienced. MYC rearrangements with non-IG partners are observed in about 3% of B-cell non-Hodgkin's lymphomas (NHL). Few studies have been dedicated to this subject until our recent paper 1 in which we reported the FISH mapping of 17 MYC-non IG translocations along with the molecular characterization of t(8;9)(q24;p13) translocations identified in two patients. The level of MYC transcript, determined in seven cases, was found to be increased as compared to that of samples without 8q24 rearrangement. Among these 7 cases, two t(3;8)(q27;q24) were detected in patients with germinal center-type diffuse large B-cell lymphoma (GC-DLBCL), UPN602 and UPN1168 (cases no.1 and 2 of this study). FISH mapping of the corresponding breakpoint regions on chromosome 8 showed that they were located 140-370 kb downstream from MYC. On chromosome 3, breakpoints were located in a 65 kb region encompassing BCL6 for case no.1, and 89-200 kb 5 0 from BCL6 exon 1 for case no. 2. In the present study, sequencing of the genomic breakpoints was performed by chromosome walking combined with long-distance PCR (Supplementary methods and Supplementary Figure 1) .
In case no. 1, sequence analysis showed that the chromosome 8 breakpoint was located 196 kb 3 0 from MYC and 10 kb from the transcriptional unit TMEM75, in an Alu sequence (Figures 1a  and 2 ) whereas the chromosome 3 breakpoint was located 5.3 kb upstream BCL6 exon 1 (Figure 1b) . Comparison of the sequences of the two derivatives chromosomes with chromosome 3 and 8 germline sequences showed a 77-82 bp deletion from chromosome 8 along with a 162-167 bp duplication of chromosome 3 sequence at the breakpoint (Figure 2 ). The translocation of the TMEM75 locus 15 kb upstream BCL6 prompted us to verify for possible TMEM75-BCL6 fusion transcripts but results were negative. 
